These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21737256)

  • 1. Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients.
    Ali AM; Ueno T; Tanaka S; Takada M; Ishiguro H; Abdellah AZ; Toi M
    Eur J Cancer; 2011 Oct; 47(15):2265-72. PubMed ID: 21737256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).
    Vasseur A; Cabel L; Tredan O; Chevrier M; Dubot C; Lorgis V; Jacot W; Goncalves A; Debled M; Levy C; Ferrero JM; Jouannaud C; Luporsi E; Mouret-Reynier MA; Dalenc F; Lemonnier J; Savignoni A; Tanguy ML; Bidard FC; Pierga JY
    Angiogenesis; 2020 May; 23(2):193-202. PubMed ID: 31773439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
    Pierga JY; Bidard FC; Autret A; Petit T; Andre F; Dalenc F; Levy C; Ferrero JM; Romieu G; Bonneterre J; Lerebours F; Bachelot T; Kerbrat P; Campone M; Eymard JC; Mouret-Reynier MA; Gligorov J; Hardy-Bessard AC; Lortholary A; Soulie P; Boher JM; Proudhon C; Charafe-Jaufret E; Lemonnier J; Bertucci F; Viens P
    Ann Oncol; 2017 Jan; 28(1):103-109. PubMed ID: 28177480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the origin of (CD105+) circulating endothelial cells.
    Strijbos MH; Verhoef C; Gratama JW; Sleijfer S
    Thromb Haemost; 2009 Aug; 102(2):347-51. PubMed ID: 19652886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients.
    Yuan DM; Zhang Q; Lv YL; Ma XQ; Zhang Y; Liu HB; Song Y
    Tumour Biol; 2015 Nov; 36(11):9031-7. PubMed ID: 26084612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
    Bidard FC; Mathiot C; Degeorges A; Etienne-Grimaldi MC; Delva R; Pivot X; Veyret C; Bergougnoux L; de Cremoux P; Milano G; Pierga JY
    Ann Oncol; 2010 Sep; 21(9):1765-1771. PubMed ID: 20233745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
    Kulka J; Tokés AM; Tóth AI; Szász AM; Farkas A; Borka K; Járay B; Székely E; Istók R; Lotz G; Madaras L; Korompay A; Harsányi L; László Z; Rusz Z; Molnár BA; Molnár IA; Kenessey I; Szentmártoni G; Székely B; Dank M
    Magy Onkol; 2009 Dec; 53(4):335-43. PubMed ID: 20071305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
    Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer.
    Fürstenberger G; von Moos R; Lucas R; Thürlimann B; Senn HJ; Hamacher J; Boneberg EM
    Br J Cancer; 2006 Feb; 94(4):524-31. PubMed ID: 16450002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
    Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination.
    Dhakal HP; Naume B; Synnestvedt M; Borgen E; Kaaresen R; Schlichting E; Wiedswang G; Bassarova A; Giercksky KE; Nesland JM
    Clin Cancer Res; 2008 Apr; 14(8):2341-50. PubMed ID: 18413823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of CD45-/CD31+/CD105+ circulating cells in the peripheral blood of patients with gynecologic malignancies.
    Yu HK; Lee HJ; Choi HN; Ahn JH; Choi JY; Song HS; Lee KH; Yoon Y; Yi LS; Kim JS; Kim SJ; Kim TJ
    Clin Cancer Res; 2013 Oct; 19(19):5340-50. PubMed ID: 23922300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.
    Ueno T; Masuda N; Kamigaki S; Morimoto T; Akiyama F; Kurosumi M; Tsuda H; Mikami Y; Tanaka S; Morita S; Toi M
    Cancer Med; 2018 Jun; 7(6):2442-2451. PubMed ID: 29733541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
    Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
    Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
    Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
    Zhou B; Yang DQ; Xie F
    Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of primary systemic chemotherapy regimen containing anthracyclines with/without taxanes in comparison to CMF in women with early breast cancer.
    Gschwantler-Kaulich D; Fink-Retter A; Hudelist G; Bachrich T; Ledesma M; Ruecklinger E; Kubista E; Singer CF
    J Chemother; 2007 Dec; 19(6):731-8. PubMed ID: 18230558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.